Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Immune Prophylaxis and Therapy in Perforating Keratoplasty: An Inquiry of Members of Corneal Section of DOG

Bertelmann E.1, Reinhard T.2, Pleyer U.1 
1Augenklinik Charité Campus Virchow-Klinikum, Humboldt Univ. Berlin; 2Augenklinik der Heinrich-Heine-Universität‚ Düsseldorf

Purpose: Different strategies are currently used for prophylaxis and therapy of immunological transplant reactions. Aim of the present study was to evaluate clinical practice in planning and treatment of perforating keratoplasty (KPL) in Germany.
Method: A questionnaire was send out to 148 members of corneal section of DOG. The return consisted of 69 (47%) questionnaires representing 69% of institutions. 39% of responses returned from institutions performing < 50 KPL / year, 15% from institutions operating > 100 KPL and 4 % from centres performing > 300 KPL / year.
Results: 13% of responders never use a HLA-matched graft, 22% choose matched grafts in every risk KPL, 1.5% use always matched grafts. In normal risk situations 1.5 % treat less than 2 weeks with topical steroids, 66% 3 - 12 months, 6.5% > 1 year, 35 % treat additionally with systemic steroids. Cyclosporine A (92%) is besides steroids (80%) the most common immunomodulatory agent in high risk situations, while methotrexate is used only by 9.5%. The duration of immunosuppressive therapy reaches from < 3 months (9%) up to > 12 months (14%). The postoperative therapy after KPL in herpes includes topical (51%) and systemic aciclovir <3 (26%) and >3 week


Zurück | Back